Literature DB >> 28116572

UCH-L1 Expressed by Podocytes: a Potentially Therapeutic Target for Lupus Nephritis?

Ji-Hong Cui1,2, Xin Xie3,4,5.   

Abstract

Systemic lupus erythematosus (SLE) is a multisystem disease affecting many organs, and the most severe complication is lupus nephritis. Podocyte injury and loss play vital roles in the pathogenesis of lupus nephritis. Studies have shown that ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is involved in the pathogenesis and progression of many diseases, such as neurodegenerative disorders, cancers, and diabetes. Recently, numerous studies have indicated that UCH-L1 was upregulated in the podocytes in immune complex-mediated glomerulonephritis. This increase was correlated with disease aggravation. In this review, we discuss the role and mechanism of UCH-L1 in the pathogenesis of many diseases and, particularly, in lupus nephritis. Hence, we highlight the role of UCH-L1 in lupus nephritis.

Entities:  

Keywords:  NF-κB; UCH-L1; lupus nephritis; podocyte

Mesh:

Substances:

Year:  2017        PMID: 28116572     DOI: 10.1007/s10753-017-0512-x

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  74 in total

1.  Effect of cyclophosphamide or azathioprine on urinary podocytes in patients with diffuse proliferative lupus nephritis.

Authors:  T Nakamura; C Ushiyama; N Shimada; K Sekizuka; I Ebihara; M Hara; H Koide
Journal:  Nephron       Date:  2001-02       Impact factor: 2.847

Review 2.  The podocyte's response to injury: role in proteinuria and glomerulosclerosis.

Authors:  S J Shankland
Journal:  Kidney Int       Date:  2006-05-10       Impact factor: 10.612

3.  Kidney-infiltrating CD4+ T-cell clones promote nephritis in lupus-prone mice.

Authors:  Akiko Okamoto; Keishi Fujio; Nelson H Tsuno; Koki Takahashi; Kazuhiko Yamamoto
Journal:  Kidney Int       Date:  2012-07-04       Impact factor: 10.612

4.  Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases.

Authors:  Joungil Choi; Allan I Levey; Susan T Weintraub; Howard D Rees; Marla Gearing; Lih-Shen Chin; Lian Li
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

Review 5.  The pathogenesis, diagnosis and treatment of lupus nephritis.

Authors:  Noa Schwartz; Beatrice Goilav; Chaim Putterman
Journal:  Curr Opin Rheumatol       Date:  2014-09       Impact factor: 5.006

Review 6.  The pathogenesis of lupus nephritis.

Authors:  Maciej Lech; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2013-08-08       Impact factor: 10.121

7.  Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis.

Authors:  N Kitamura; Y Matsukawa; M Takei; S Sawada
Journal:  J Int Med Res       Date:  2009 May-Jun       Impact factor: 1.671

8.  β-cell dysfunctional ERAD/ubiquitin/proteasome system in type 2 diabetes mediated by islet amyloid polypeptide-induced UCH-L1 deficiency.

Authors:  Safia Costes; Chang-jiang Huang; Tatyana Gurlo; Marie Daval; Aleksey V Matveyenko; Robert A Rizza; Alexandra E Butler; Peter C Butler
Journal:  Diabetes       Date:  2010-10-27       Impact factor: 9.461

Review 9.  NF-kappaB signalling in chronic kidney disease.

Authors:  Gopala Rangan; Yiping Wang; David Harris
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

Review 10.  The Role of Autophagy in Lupus Nephritis.

Authors:  Linlin Wang; Helen Ka Wai Law
Journal:  Int J Mol Sci       Date:  2015-10-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.